Condition: Advanced Solid Tumor · Lung Squamous Cell Carcinoma · Hepatocellular Carcinoma · Sponsor: Shanghai JMT-Bio Inc.
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors
This description comes directly from the study's public registry record.
Liang Ting bo, Ph.D · 0571-87236666 · liangtingbo@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The First Affilicated Hospital,Zhejiang University School of Medicine | Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07275073